Kidney Disease as a Driver of Immunosenescence
Journal of the American Society of Nephrology · 2026-02 · 37 (2) · 405-416
DOI: 10.1681/asn.0000000896 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 12.09.2025. Verfasst von Zhuolun Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusett…. Hauptthemen laut MEDLINE: Immunosenescence, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Immunosenescence, a state marked by immune dysfunction, chronic low-grade inflammation, and impaired pathogen defense, is accelerated in CKD. CKD promotes systemic inflammation through the accumulation of uremic toxins, oxidative stress, and dysregulated immune signaling, all driving premature aging of both innate and adaptive immune cells. These mechanisms result in dysregulated immune activation and impaired surveillance, thereby aggravating kidney damage and increasing the risk for comorbidities. Despite removing uremic toxins, dialysis may further accelerate immunosenescence by exposing immune cells to oxidative and antigenic stress, inducing telomere shortening and T-cell exhaustion. Kidney transplantation can partially reverse CKD-induced immunosenescence by restoring kidney function. Commonly used immunosuppressive agents, however, may further promote immunosenescence by impairing thymic function, depleting naïve T cells, and suppressing natural killer cell activity. However, mammalian target of rapamycin (mTOR) inhibitors have shown anti-aging effects by promoting autophagy and inhibiting proinflammatory pathways. Therapeutic strategies targeting immunosenescence in CKD have been gaining momentum. Senotherapeutics can eliminate senescent cells and reduce senescence-associated secretory phenotype (SASP)–mediated inflammation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, caloric restriction, microbiome modulation, mesenchymal stem cell therapies, and KRTs also offer the potential to slow accelerated immunosenescence as a consequence of CKD. Here, we provide a comprehensive overview of the mechanisms linking CKD and immunosenescence, along with emerging therapeutic strategies that have the potential to target premature aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Renal Division, Transplant Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Zhuolun Song, Yao Xiao, Hao Zhou
Förderung
- NIH HHS
- NIAID NIH HHS
- NIA NIH HHS
- Hevolution Foundation
- National Institutes of Health
- Pablo and Almudena Legorreta Kidney Health Research Fund
Zitieren
APA
Song, Z., Tsou, S., Martin, F., Kayumov, M., Xiao, Y., Zhou, H., Abdi, R., & Tullius, S. G. (2026). Kidney Disease as a Driver of Immunosenescence. Journal of the American Society of Nephrology, 37(2), 405-416. https://doi.org/10.1681/asn.0000000896
Vancouver
Song Z, Tsou S, Martin F, Kayumov M, Xiao Y, Zhou H, et al. Kidney Disease as a Driver of Immunosenescence. Journal of the American Society of Nephrology. 2026;37(2):405-416. doi:10.1681/asn.0000000896
BibTeX
@article{Song2026,
author = {Song, Zhuolun and Tsou, Sarah and Martin, Friederike and Kayumov, Mukhammad and Xiao, Yao and Zhou, Hao and Abdi, Reza and Tullius, Stefan G},
title = {Kidney Disease as a Driver of Immunosenescence},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {2},
pages = {405--416},
doi = {10.1681/asn.0000000896}
}
EUVIMED